Background: Bevacizumab is the representative drug in antiangiogenic therapy for lung cancer. However, it induced resistance in some neoplasm. Anlotinib, a novel multi-target tyrosine kinase inhibitor ...

Introduction: The combination of atezolizumab, an immune checkpoint inhibitor (ICI), and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is the first choice for systemic therapy in ...

The median progression-free survival was 15.0 months with TACE plus durvalumab and bevacizumab and 8.2 months with TACE alone. Durvalumab plus bevacizumab and transarterial chemoembolization (TACE ...

NCT01279707 Monoclonal antibodies in recurrent or refractory B cell acute lymphoblastic leukaemia (ALL) (MARALL) Queen Mary University of London, England NCT01920932 Adcetris (brentuximab vedotin ...

The International Federation of Gynecology and Obstetrics (FIGO) staging systems for vulva, cervix, endometrium, and sarcomas have been revised for the first time in over a decade. The purpose of ...

Sigvotatug vedotin is under clinical development by Pfizer and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData, Phase III drugs for Non-Small Cell Lung Cancer have a 46% ...

Telisotuzumab vedotin is under clinical development by AbbVie and currently in Pre-Registration for Non-Small Cell Lung Cancer. According to GlobalData, Pre-Registration drugs for Non-Small Cell Lung ...

Objective To assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular ...

Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer (NSCLC) whose tumours overexpress c-Met. The c-Met protein ...

In April 2024, the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK ® (tisotumab vedotin-tftv) for the ...

In 2025, AbbVie expects to continue advancing its antibody-drug conjugate (ADC) assets and net US approval for its cMET-targeting ADC telisotuzumab vedotin (Teliso-V) in non-small cell lung cancer ...